Assessing the potential of autonomous submarine gliders for ecosystem monitoring across multiple trophic levels (plankton to cetaceans) and pollutants in shallow shelf seas

A combination of scientific, economic, technological and policy drivers is behind a recent upsurge in the use of marine autonomous systems (and accompanying miniaturized sensors) for environmental mapping and monitoring. Increased spatial–temporal resolution and coverage of data, at reduced cost, is particularly vital for effective spatial management of highly dynamic and heterogeneous shelf environments. This proof-of-concept study involves integration of a novel combination of sensors onto buoyancy-driven submarine gliders, in order to assess their suitability for ecosystem monitoring in shelf waters at a variety of trophic levels. Two shallow-water Slocum gliders were equipped with CTD and fluorometer to measure physical properties and chlorophyll, respectively. One glider was also equipped with a single-frequency echosounder to collect information on zooplankton and fish distribution. The other glider carried a Passive Acoustic Monitoring system to detect and record cetacean vocalizations, and a passive sampler to detect chemical contaminants in the water column. The two gliders were deployed together off southwest UK in autumn 2013, and targeted a known tidal-mixing front west of the Isles of Scilly. The gliders’ mission took about 40 days, with each glider travelling distances of >1000 km and undertaking >2500 dives to depths of up to 100 m. Controlling glider flight and alignment of the two glider trajectories proved to be particularly challenging due to strong tidal flows. However, the gliders continued to collect data in poor weather when an accompanying research vessel was unable to operate. In addition, all glider sensors generated useful data, with particularly interesting initial results relating to subsurface chlorophyll maxima and numerous fish/cetacean detections within the water column. The broader implications of this study for marine ecosystem monitoring with submarine gliders are discussed

Biogeochemical processes in the active layer and permafrost of a high Arctic fjord valley

Warming of ground is causing microbial decomposition of previously frozen sedimentary organic carbon in Arctic permafrost. However, the heterogeneity of the permafrost landscape and its hydrological processes result in different biogeochemical processes across relatively small scales, with implications for predicting the timing and magnitude of permafrost carbon emissions. The biogeochemical processes of iron- and sulfate-reduction produce carbon dioxide and suppress methanogenesis. Hence, in this study, the biogeochemical processes occurring in the active layer and permafrost of a high Arctic fjord valley in Svalbard are identified from the geochemical and stable isotope analysis of aqueous and particulate fractions in sediment cores collected from ice-wedge polygons with contrasting water content. In the drier polygons, only a small concentration of organic carbon (<5.40 dry weight%) has accumulated. Sediment cores from these drier polygons have aqueous and solid phase chemistries that imply sulfide oxidation coupled to carbonate and silicate dissolution, leading to high concentrations of aqueous iron and sulfate in the pore water profiles. These results are corroborated by δ34S and δ18O values of sulfate in active layer pore waters, which indicate the oxidative weathering of sedimentary pyrite utilising either oxygen or ferric iron as oxidising agents. Conversely, in the sediments of the consistently water-saturated polygons, which contain a high content of organic carbon (up to 45 dry weight%), the formation of pyrite and siderite occurred via the reduction of iron and sulfate. δ34S and δ18O values of sulfate in active layer pore waters from these water-saturated polygons display a strong positive correlation (R2 = 0.98), supporting the importance of sulfate reduction in removing sulfate from the pore water. The significant contrast in the dominant biogeochemical processes between the water-saturated and drier polygons indicates that small-scale hydrological variability between polygons induces large differences in the concentration of organic carbon and in the cycling of iron and sulfur, with ramifications for the decomposition pathway of organic carbon in permafrost environments

Female Mucopolysaccharidosis IIIA Mice Exhibit Hyperactivity and a Reduced Sense of Danger in the Open Field Test

Reliable behavioural tests in animal models of neurodegenerative diseases allow us to study the natural history of disease and evaluate the efficacy of novel therapies. Mucopolysaccharidosis IIIA (MPS IIIA or Sanfilippo A), is a severe, neurodegenerative lysosomal storage disorder caused by a deficiency in the heparan sulphate catabolising enzyme, sulfamidase. Undegraded heparan sulphate accumulates, resulting in lysosomal enlargement and cellular dysfunction. Patients suffer a progressive loss of motor and cognitive function with severe behavioural manifestations and premature death. There is currently no treatment. A spontaneously occurring mouse model of the disease has been described, that has approximately 3% of normal enzyme activity levels. Behavioural phenotyping of the MPS IIIA mouse has been previously reported, but the results are conflicting and variable, even after full backcrossing to the C57BL/6 background. Therefore we have independently backcrossed the MPS IIIA model onto the C57BL/6J background and evaluated the behaviour of male and female MPS IIIA mice at 4, 6 and 8 months of age using the open field test, elevated plus maze, inverted screen and horizontal bar crossing at the same circadian time point. Using a 60 minute open field, we have demonstrated that female MPS IIIA mice are hyperactive, have a longer path length, display rapid exploratory behaviour and spend less time immobile than WT mice. Female MPS IIIA mice also display a reduced sense of danger and spend more time in the centre of the open field. There were no significant differences found between male WT and MPS IIIA mice and no differences in neuromuscular strength were seen with either sex. The altered natural history of behaviour that we observe in the MPS IIIA mouse will allow more accurate evaluation of novel therapeutics for MPS IIIA and potentially other neurodegenerative disorders

Superhumps, Magnetic Fields and the Mass-ratio in AM Canum Venaticorum

We show that the observed K-velocities and periodicities of AM CVn can be reconciled given a mass ratio of 0.22 and a secondary star with a modest magnetic field of surface strength of order 1 Tesla. We see that the new mass ratio implies that the secondary is most likely semi-degenerate. The effect of the field on the accretion disc structure is examined. The theory of precessing discs and resonant orbits is generalised to encompass higher order resonances than 3:2 and shown to retain consistency with the new mass ratio.Comment: 6 pages, 4 figures, to appear in Monthly Notices of the Royal Astronomical Societ

Iron localization in Acarospora colonizing schist on Signy Island

A small, inconspicuous lichen, Acarospora cf. badiofusca, was discovered colonizing ironstained quartz mica schists on the lower slope of Manhaul Rock, a recently exposed nunatak on the McLeod Glacier, Signy Island, South Orkney Islands. Thallus colour ranged from rust on exposed rock surfaces to paler orange and green in shaded crevices. This study addressed the hypothesis that colour reflects element localization, and considered substance localization within lichen tissues and responses to stress. Electron microprobe analysis of specimens confirmed that Fe is localized principally in the outer rust-coloured part of the cortex, confirming that the colour reflects Fe localization. Oxalates, widely reported as contributing to tolerance mechanisms to environmental stress, were not detected using X-ray diffraction. The upper thallus surface consisted of sub-micron particulate phases containing Fe, Al and O, suggesting mixed oxide/ hydroxide phases are present and play a role in photoprotection

Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.

IntroductionMucopolysaccharidosis (MPS) IVA or Morquio A syndrome is an autosomal recessive lysosomal storage disorder (LSD) caused by deficiency of the N-acetylgalactosamine-6-sulfatase (GALNS) enzyme, which impairs lysosomal degradation of keratan sulphate and chondroitin-6-sulphate. The multiple clinical manifestations of MPS IVA present numerous challenges for management and necessitate the need for individualised treatment. Although treatment guidelines are available, the methodology used to develop this guidance has come under increased scrutiny. This programme was conducted to provide evidence-based, expert-agreed recommendations to optimise management of MPS IVA.MethodsTwenty six international healthcare professionals across multiple disciplines, with expertise in managing MPS IVA, and three patient advocates formed the Steering Committee (SC) and contributed to the development of this guidance. Representatives from six Patient Advocacy Groups (PAGs) were interviewed to gain insights on patient perspectives. A modified-Delphi methodology was used to demonstrate consensus among a wider group of healthcare professionals with experience managing patients with MPS IVA and the manuscript was evaluated against the validated Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument by three independent reviewers.ResultsA total of 87 guidance statements were developed covering five domains: (1) general management principles; (2) recommended routine monitoring and assessments; (3) disease-modifying interventions (enzyme replacement therapy [ERT] and haematopoietic stem cell transplantation [HSCT]); (4) interventions to support respiratory and sleep disorders; (5) anaesthetics and surgical interventions (including spinal, limb, ophthalmic, cardio-thoracic and ear-nose-throat [ENT] surgeries). Consensus was reached on all statements after two rounds of voting. The overall guideline AGREE II assessment score obtained for the development of the guidance was 5.3/7 (where 1 represents the lowest quality and 7 represents the highest quality of guidance).ConclusionThis manuscript provides evidence- and consensus-based recommendations for the management of patients with MPS IVA and is for use by healthcare professionals that manage the holistic care of patients with the intention to improve clinical- and patient-reported outcomes and enhance patient quality of life. It is recognised that the guidance provided represents a point in time and further research is required to address current knowledge and evidence gaps

Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance.

IntroductionMucopolysaccharidosis (MPS) VI or Maroteaux-Lamy syndrome (253200) is an autosomal recessive lysosomal storage disorder caused by deficiency in N-acetylgalactosamine-4-sulfatase (arylsulfatase B). The heterogeneity and progressive nature of MPS VI necessitates a multidisciplinary team approach and there is a need for robust guidance to achieve optimal management. This programme was convened to develop evidence-based, expert-agreed recommendations for the general principles of management, routine monitoring requirements and the use of medical and surgical interventions in patients with MPS VI.Methods26 international healthcare professionals from various disciplines, all with expertise in managing MPS VI, and three patient advocates formed the Steering Committee group (SC) and contributed to the development of this guidance. Members from six Patient Advocacy Groups (PAGs) acted as advisors and attended interviews to ensure representation of the patient perspective. A modified-Delphi methodology was used to demonstrate consensus among a wider group of healthcare professionals with expertise and experience managing patients with MPS VI and the manuscript has been evaluated against the validated Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument by three independent reviewers.ResultsA total of 93 guidance statements were developed covering five domains: (1) general management principles; (2) recommended routine monitoring and assessments; (3) enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT); (4) interventions to support respiratory and sleep disorders; (5) anaesthetics and surgical interventions. Consensus was reached on all statements after two rounds of voting. The greatest challenges faced by patients as relayed by consultation with PAGs were deficits in endurance, dexterity, hearing, vision and respiratory function. The overall guideline AGREE II assessment score obtained for the development of the guidance was 5.3/7 (where 1 represents the lowest quality and 7 represents the highest quality of guidance).ConclusionThis manuscript provides evidence- and consensus-based recommendations for the management of patients with MPS VI and is for use by healthcare professionals that manage the holistic care of patients with the intention to improve clinical- and patient-reported outcomes and enhance patient quality of life. It is recognised that the guidance provided represents a point in time and further research is required to address current knowledge and evidence gaps